



Media Release – Ad-hoc announcement pursuant to Art. 53 LR

Medacta Group reports continued significant above-market revenue growth of 18.5% in constant currency in 2025¹

- **FY 2025 revenue accelerated to Euro 683.8 million, up 18.5% in c.c.¹ or 15.8% in Euro**
- **Substantial revenue growth across all geographic markets**
- **Continuous outstanding performance in all business lines due to its differentiating innovations**
- **258 new jobs created to foster further growth**

CASTEL SAN PIETRO, 3 February 2026 – Medacta Group SA (“Medacta”, SIX:MOVE) today announces its full year 2025 preliminary unaudited revenue.

Francesco Siccardi, CEO of Medacta, commented: *“We are very pleased with our continued outstanding growth performance, across all geographic markets and business lines against strong prior year comparables. Our dedication to improve patient outcomes and patient satisfaction drives our strong focus on differentiating innovations for minimally invasive techniques and personalized solutions as well as on surgeon-specific structured medical education. These key pillars, coupled with the constant expansion of our salesforce, are at the base of our successful expansion strategy. I am proud of the entire Medacta team in delivering such outstanding results.”*

In 2025, Medacta recorded Group revenue of Euro 683.8 million, an increase of 18.5% in constant currency and an increase of 15.8% in Euro. The acquisition of Parcus Medical in March 2025, the integration of which has been concluded, contributed approximately 1.5% to Group revenue.

Medacta reported another year of outstanding growth in all geographic markets and continued superior growth across all business lines. This was achieved by the constant launch of our differentiating innovations across all business lines, our continued efforts in medical education and the attraction of new surgeons supported by our expanded sales force.

In 2025, Medacta progressed to further strengthen and optimize its supply chain. Medacta has almost finalized its new fully automated warehouse in Italy. This new setup will facilitate and reduce handling costs primarily in Europe, Middle East and Africa (EMEA).

Substantial revenue growth across all geographic areas

Medacta achieved substantial growth rates across all geographies. The largest contributions to growth came from Asia Pacific and North America, growing 23.0% and 19.0% respectively, followed by EMEA increasing 15.2%, all in c.c.. Latin America, which is the smallest geographic area, advanced a superb 42.2% in c.c..

Revenue distribution by geographic area:

(Euro million)	FY 2025	FY 2024	Growth in Euro	Growth in constant currency
EMEA*	327.5	283.7	15.4%	15.2%
North America	204.5	179.3	14.1%	19.0%
Asia Pacific	134.8	115.1	17.1%	23.0%
Latin America	17.0	12.4	36.7%	42.2%
TOTAL	683.8	590.6	15.8%	18.5%

* Europe, Middle East and Africa

Excellent revenue expansion across all product lines

Hip revenues rose again in double-digits by 11.9% in c.c., to Euro 270.5 million, with particularly outstanding performance in Asia Pacific and North America. The growth was mainly the result of Medacta's excellent Anterior Minimally Invasive Surgery (AMIS) platform, which allows an easily reproducible technique that delivers significant benefits to patients, surgeons as well as healthcare systems ^[1,2,3].

Knee revenues advanced by another outstanding 20.7% in c.c. to Euro 284.1 million. All geographic regions contributed to this growth, but mainly attributable to North America as well as EMEA. Next to Medacta's personalized Kinematic Alignment platform MyKA, GMK SpheriKA, the first knee implant specifically designed for the Kinematic Alignment technique, promoted this excellent performance. In 2025, the global roll-out of GMK SpheriKA further advanced including the UK, Canada and Japan. 2025 saw an additional boost in the adoption of the NextAR Knee system as well as for cementless and SensiTiN, Medacta's low-ion-release, options.

Extremities, which include both, Shoulder and Sportsmed, delivered another notable revenue growth of 46.2% in c.c. to Euro 72.1 million with both sub-businesses contributing to this great progress. In particular, Medacta's Shoulder System, supported by advanced technologies such as Medacta's MyShoulder patient-specific cutting guides as well as NextAR Shoulder Augmented Reality surgical application delivered an excellent performance, achieving market leading position in key geographies.

Spine revenues increased by 12.2% in c.c. to Euro 57.0 million. The good acceleration was strongly sustained by Medacta's technologies, particularly by NextAR Spine, and the Rod Optimizer platform, which support surgeons in designing the optimal surgical strategy based on each patient's individual anatomy and helps to streamline the surgical workflow. An expansion was seen across all geographies but was primarily supported by EMEA as well as Asia Pacific.

Revenue distribution by business line:

(Euro million)	FY 2025	FY 2024	Growth in Euro	Growth in constant currency
Hip	270.5	247.3	9.4%	11.9%
Knee	284.1	241.2	17.8%	20.7%
Extremities**	72.1	50.3	43.4%	46.2%
Spine	57.0	51.8	10.2%	12.2%
TOTAL	683.8	590.6	15.8%	18.5%

** Extremities include Shoulder and Sportsmed revenues

These preliminary revenue figures are unaudited for the period ending 31 December 2025 and therefore, are subject to change. The Group will announce its **2025 Full Year Results on 13 March 2026**.

Webcast Today at 3:00 pm (CET)

Medacta Group SA will present its 2025 preliminary unaudited revenue during a webcast today at 3:00 p.m. (CET). The call will be headed by Francesco Siccardi (CEO) and Corrado Farsetta (CFO) and will be held in English.

Live-Link:

<https://87399.choruscall.eu/links/medacta260203.html>

Dial-in numbers for conference call only:

Belgium: +32 28948063
Denmark: +45 32727525
France: +33 170918704
Germany: +49 6917415712
Ireland: +353 15269444
Italy: +39 02 802 09 11
Spain: +34 917699498
Sweden: +46 850510030
Switzerland: +41 225954728
UK: +44 1 212818004
USA: +1 718 7058796

Contact

Medacta

Anja Pomrehn

Group VP Sustainability and Investor & Media Relations

Phone: +41 91 696 14 95

investor.relations@medacta.ch

About Medacta

Medacta is a global key player specializing in the design, production, and distribution of innovative, personalized, and sustainable solutions for joint replacement, sports medicine, and spine surgery. Established in 1999 in Switzerland, Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Through close collaboration with expert surgeons globally, continuous investments in R&D, and the adoption of cutting-edge technologies, Medacta's innovation prioritizes minimally invasive surgery and personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 70 countries. Follow us on [Medacta.com](https://www.medacta.com), [Medacta TV](#), [YouTube](#), [LinkedIn](#) and [X](#).

Disclaimer

This media release has been prepared by Medacta Group SA ('Medacta' and together with its subsidiaries, 'we', 'us' or the 'Group'). The information contained in the media release does not purport to be comprehensive and is not to be taken as containing any securities advice, recommendation, offer or invitation to subscribe for, purchase or redeem any securities regarding Medacta.

Forward-looking information

This media release has been prepared by Medacta and includes forward-looking information and statements concerning the outlook for its business. These statements are based on current expectations, estimates and projections about the factors that may affect its future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as 'expects', 'believes', 'estimates', 'targets', 'plans', 'outlook' or similar expressions. Although Medacta believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.

Related Trademarks

Medacta Group Related Trademarks are registered at least in Switzerland. The products and services listed below may not be all-inclusive, and other Medacta products and services not listed below may be covered by one or more trademarks. The products and services below may be covered by additional trademarks not listed below. Note that Swiss trademarks may have foreign counterparts.

AMIS®, GMK® SpheriKA, MyShoulder®, MyKA™, SensiTiN™, NextAR™, NextAR™ Spine.

Notes**1) Alternative Performance Measures:**

This press release contains certain information that it refers to as "constant currency" or c.c., which is a non-IFRS financial measure and represents the total change between periods excluding the effect of changes in foreign currency exchange rates. The Group believes that the reconciliations of changes in constant currency provide useful supplementary information to investors in light of fluctuations in

foreign currency exchange rates. Furthermore, the Group believes that constant currency measures provide additional useful information on the Group's operational performance and is consistent with how the business performance is measured internally. Definitions of Alternative Performance Measures and reconciliations between such measures and their IFRS counterparts may be found on the financial reports available on our website at: <https://www.medacta.com/EN/financial-reports-and-presentations>

Above-market revenue growth:

This press release contains information that refers to "above-market revenue growth", which is in reference to data from The Orthopaedic Industry Annual Report® published by Orthoworld® Inc., published May 2025.

References

- [1] Vasina PG, Rossi R, Giudice GM, Palumbi P. Hip arthroplasty through the anterior minimally invasive approach. Sphera 2010;6(12) - Speciale Ortopedia
- [2] Christofilopoulos P, Roussos C, Lädermann A, Lübcke A, Hoffmeyer P. Socioeconomic aspects of total hip arthroplasty. A comparison between anterior minimally invasive surgery and standard lateral approach. Poster at the 12th EFORT Congress, Copenhagen, Denmark: 1-4 June 2011.
- [3] Sebečić B, Starešinić M, Culjak V, Japjec M. Minimally invasive hip arthroplasty: advantages and disadvantages. Med Glas (Zenica). 2012 Feb;9(1):160-5. PMID: 22634930.